/
NTHI
$4.43-$0.15 (-3.28%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$118.8M
26M shares
52-week range
$3.20 – $12.99
13% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.36%
Moderate
Price (6 mo)
Loading chart…
Change$-7.68
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2025 | |
|---|---|
| Revenue | $40.0K |
| Cost of revenue | $0 |
| Gross profit | $40.0K |
| Gross margin | 100.0% |
| R&D | $3.6M |
| Operating income | −$58.2M |
| EBITDA | −$59.6M |
| Net income | −$62.1M |
| Net margin | -155404.4% |
| EPS (diluted) | -3.23 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $39990 | $-0.70 | $-0.96–$-0.54 | 2 |
| 2027 | $39990 | $-0.62 | $-0.84–$-0.40 | 2 |
| 2028 | $39990 | $-0.67 | $-0.67–$-0.67 | 1 |
| 2029 | $65M | $0.02 | $0.02–$0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
www.neonc.com- Employees
- 5
- IPO / List date
- Mar 26, 2025
- HQ
- CALABASAS, CA
Held by traders on TradeandTell
No one on the platform currently holds NTHI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NTHI as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NTHI yet.
